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COVID-19, the illness caused by SARS-CoV-2, has a wide-ranging clinical spectrum
that, in the worst-case scenario, involves a rapid progression to severe acute respira-
tory syndrome and death. Epidemiological data show that obesity and diabetes are
among the main risk factors associated with high morbidity and mortality. The
increased susceptibility to SARS-CoV-2 infection documented in obesity-related met-
abolic derangements argues for initial defects in defence mechanisms, most likely
due to an elevated systemic metabolic inflammation (“metaflammation”). The NLRP3
inflammasome is a master regulator of metaflammation and has a pivotal role in the
pathophysiology of either obesity or diabetes. Here, we discuss the most recent find-
ings suggesting contribution of NLRP3 inflammasome to the increase in complica-
tions in COVID-19 patients with diabesity. We also review current pharmacological
strategies for COVID-19, focusing on treatments whose efficacy could be due, at
least in part, to interference with the activation of the NLRP3 inflammasome.
Linked Articles: This article is part of a themed issue on The Pharmacology of
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1 | METAFLAMMATION IN OBESITY-
RELATED METABOLIC DISORDERS AND
COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is a novel member of human betacoronavirus (mutational ssRNA
viruses) causing the disease named COVID-19 (for coronavirus dis-
ease 2019), which was recognized as a pandemic on March 11, 2020,
by the World Health Organization (WHO). COVID-19 is a syndrome
with a wide clinical spectrum. It can be asymptomatic or, in the major-
ity of cases, cause mild symptoms that are indistinguishable from
other respiratory infections, but it may also lead to a rapid progression
to severe acute respiratory syndrome (SARS), with respiratory failure
and death (Zhou et al., 2020).
The activation of signalling receptors of the innate immune sys-
tem is the first step of the physiological response to virus infection.
However, when excessive, this innate immune system activation may
evoke hyperinflammation and tissue damage in patients with severe
COVID-19, making it an important aspect of the pathophysiology of
this syndrome (Netea et al., 2020).
Abbreviations: AnxA1, annexin A1; ARDS, acute respiratory distress syndrome; BTK,
Bruton's tyrosine kinase; COVID-19, coronavirus disease 2019; FPR2, formyl-peptide
receptor 2; ICU, intensive care unit; SARS, severe acute respiratory syndrome; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2; T2DM, Type 2 diabetes mellitus; TLR, toll-
like receptor.
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Older people are more likely to suffer from the most serious com-
plications of SARS-CoV-2 infection and this susceptibility is likely to
be due to the physiological decrease in the efficacy of the immune
system and the simultaneous increase in age-related inflammatory
response (Latz & Duewell, 2018). Moreover, aging and the modern
lifestyle typical of Western societies are both associated with an
increase in co-morbidities, such as “diabesity,” the association of obe-
sity and diabetes, which defines a combination of primarily metabolic
disorders evoked by impairment of both lipids and sugar metabolism
(Potenza et al., 2017; Tschop & DiMarchi, 2012). The close relation-
ship existing between impaired metabolism and immunity in obese-
related metabolic derangements is well documented, and the term
“metaflammation” has been coined to indicate a pathophysiological
inflammatory response resulting from metabolic alterations and dys-
functions (Hotamisligil, 2017; Mastrocola et al., 2018). An increasing
number of studies report that patients with severe obesity or Type
2 diabetes mellitus (T2DM) exhibit an increased circulating concentra-
tion of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α
(C. Huang et al., 2020). The metaflammation induced in response to
excessive intake of calories by adipose tissue may subsequently
involve other organs, such as skeletal muscle, liver, heart, and lung,
leading to metabolic and cardiovascular alterations.
Compared with people of a normal weight, obese individuals have
an increased susceptibility to develop chronic diseases and infections
(Huttunen & Syrjanen, 2010; Milner & Beck, 2012; Wolowczuk
et al., 2008). Patients with T2DM developing COVID-19 are twice as
likely to require ventilation and intensive care unit (ICU) support, and
their mortality is threefold higher than in non-diabetic COVID-19
patients (W. J. Guan, Ni, et al., 2020; X. Yang et al., 2020). Obesity
carries a fivefold increased risk of developing severe pneumonia from
COVID-19 (Cai et al., 2020), and diabesity is a well-recognized
risk factor for severe infections (Almond, Edwards, Barclay, &
Johnston, 2013; Huttunen & Syrjanen, 2013), sleep apnoea (Dixon &
Peters, 2018), poor immune response, and scant outcomes in patients
with respiratory disease (Green & Beck, 2017). According to US data,
37% of 3,615 hospitalized COVID-19 cases were obese, and the obe-
sity increased the odds of ICU admission (Lighter et al., 2020). In a
French study enrolling COVID-19 patients admitted to the ICU, the
requirement for ventilation was increased by sevenfold in patients
with a body mass index (BMI) >35 kg/m2, and this was independent
of age and presence of diabetes or hypertension (Simonnet
et al., 2020). Direct comparison of odds ratios for the risk of SARS in
obese and/or diabetic subjects, in comparison with other lung disor-
ders, such as asthma, pulmonary hypertension, and pneumonia in the
same populations, would be useful to understand the specific contri-
bution of SARS-CoV-2 for both severity and prevalence of a specific
organ injury. Adipocytes express high levels of ACE2, which is the
receptor for SARS-CoV-2 (Gembardt et al., 2005; Gupte et al., 2008).
Similar to infections with either human or simian immunodeficiency
virus (HIV/SIV), high virus concentrations in adipose tissue may be
secondary to high levels of binding cells (CD4+). Indeed, it is possible
that SARS-CoV-2 accesses adipose tissue more easily due to the high
ACE2 expression, possibly generating a viral “reservoir” in adipose
tissue (Wanjalla et al., 2019). So far, most of the experimental findings
have evaluated ACE2 gene expression only, whereas its parallelism
with protein expression as well as enzyme functionality still needs to
be confirmed to clarify the effective role of ACE2 in facilitating SARS-
CoV-2 localization in adipose tissue.
As widely documented (Huttunen & Syrjanen, 2013; Singh,
Gupta, Ghosh, & Misra, 2020), obese people and individuals with
T2DM are more likely to develop a dysfunctional immune response
that provokes viral infection and fails to eliminate the pathogen. Spe-
cific reasons for this are still not understood, even if one reasonable
explanation could be an excessive local inflammatory response, often
due to an over-activation of specific inflammatory pathways, includ-
ing, but not limited to, the NLRP3 inflammasome.
2 | THE NLRP3 INFLAMMASOME AND ITS
ROLE IN VIRAL INFECTION
The NLRP3 inflammasome is a large, multimeric protein complex
assembled within the cell upon the recognition of unique molecular
patterns by a germline-encoded pattern recognition receptor (Y. Yang,
Wang, Kouadir, Song, & Shi, 2019). Among the pattern recognition
receptors known to form inflammasomes, NLRP3 belongs to the fam-
ily containing both a nucleotide-binding oligomerization domain
(NOD) and proteins containing a leucine-rich repeat sequence. NLRP3
is expressed in several cell types, as innate immunity, endothelial,
haematopoietic, lung epithelial, kidney, and cardiac cells (Ratajczak &
Kucia, 2020). We and others have previously demonstrated that
NLRP3 inflammasome over-activation contributes to the pathogenesis
of cardio-metabolic disorders (Mastrocola, Collino, et al., 2016;
O'Riordan et al., 2019; Y. Wang et al., 2020; Zuurbier et al., 2019),
whereas NLRP3 deficiency results in reduced systemic inflammation,
along with a decreased immune cell activation and improved insulin
resistance (Grant & Dixit, 2013; Vandanmagsar et al., 2011). The
NLRP3 inflammasome is also a crucial player in immune defence of
the host against many pathogens, including viruses (Z. Xu et al., 2020;
Zhao & Zhao, 2020). Once activated, its amino-terminal pyrin domain
is able to recruit the downstream adaptor protein apoptosis-
associated speck-like protein containing a caspase-recruitment
domain (ASC). In addition, the amino-terminal pyrin domain triggers
the assembly of the scaffold complex important to recruit the
inflammasome effector, pro-caspase-1, which becomes activated.
Active form of caspase-1 cleaves both pro-IL-1β and pro-IL-18 into
their biologically active forms (Dinarello, 2009). Caspase-1 can also
activate an additional substrate, the gasdermin D, which mediates
pyroptosis by creating pore channels in cell membranes. Pyroptosis is
a lytic form of necrosis used by the innate immune system to disrupt
pathogen replication and intracellular accumulation, due to the forma-
tion of pore-induced intracellular traps (Jorgensen, Zhang, Krantz, &
Miao, 2016). Despite its role in facilitating pathogen clearance,
inflammasome activation can also be detrimental to the host by
enhancing viral dissemination (Lupfer, Malik, & Kanneganti, 2015). To
date, it is still unclear whether SARS-CoV-2 activates the NLRP3
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inflammasome (Yap, Moriyama, & Iwasaki, 2020), but this is likely, as
SARS-CoV also activates the NLRP3 inflammasome by modulating
either ion channel activity or ASC ubiquitination. Moreover, after
binding to SARS-CoV, ACE2 is internalized, leading to high cytosolic
levels of angiotensin II, which is known to act as an activator of the
NLRP3 inflammasome in lung, kidney cells, and cardiomyocytes
(Deshotels, Xia, Sriramula, Lazartigues, & Filipeanu, 2014; S. Wang
et al., 2008). In particular, activation of the ACE2/Ang(1–7) axis leads
to inhibition of NLRP3 inflammasomes, associated with the down-
regulation of angiotensin II-induced mir-21 (Sun et al., 2017). It is pos-
sible that a similar pathway may be activated by SARS-CoV-2. In addi-
tion, given that caspase-1 affects expression of several innate
immunity genes and viral replication (Bauer et al., 2012), the NLRP3
inflammasome may alter cellular physiology and homeostasis also
modulating gene expression, leading to altered innate antiviral
defence pathways and affecting, therefore, host responsiveness to
pathogens like SARS-CoV-2.
Diabesity is a high-risk factor for both influenza infections and
hospitalization for respiratory illness during seasonal influenza
(Karlsson, Sheridan, & Beck, 2010; Kwong, Campitelli, &
Rosella, 2011). Thus, we may speculate that the chronic over-
activation of the NLRP3 inflammasome, due to metabolic impair-
ments, may contribute to alterations in the innate immune
response to viral infection, making it more permissive and severe
(Figure 1).
3 | THE NLRP3 INFLAMMASOME AND ITS
INVOLVEMENT IN THE CYTOKINE STORM
The activation of both innate and adaptive immunity after recognition
of viral antigens produces a large amount of proinflammatory
cytokines and chemokines even in moderate cases of COVID-19. In
some patients, this activation is excessive, leading to a “cytokine
storm,” which in turn causes severe lung injury, multiple organ failure,
and, eventually, death (Sarzi-Puttini et al., 2020; Z. Xu et al., 2020).
The mechanisms by which SARS-CoV-2 subverts the body's innate
antiviral cytokine responses are yet to be elucidated. Nevertheless,
most recent research on SARS-CoV suggests that pyroptosis may
have a pivotal role. Pyroptosis is a form of programmed cell death in a
highly inflammatory state, that is commonly observed with cytopathic
viruses (Fink & Cookson, 2005). As mentioned before, the NLRP3
inflammasome regulates pyroptosis by gasdermin D-mediated mem-
brane rupture along with spontaneous release of cytosolic contents
into the extracellular spaces. The activation of pyroptosis in alveolar
macrophages and in recruited monocyte-derived macrophages by
SARS-CoV-2 aggravates pneumonia and acute respiratory distress
syndrome (ARDS). The release of alarmins, including viral particles,
ATP, ROS, and cytokines, chemokines, and LDH, elicits an immediate
reaction from surrounding immune cells, inducing a pyroptotic chain
reaction. Different studies have reported elevated levels of LDH, a
cytosolic enzyme that is measured for monitoring pyroptosis
(Rayamajhi, Zhang, & Miao, 2013), in patients with the severe form of
the disease and worse outcomes (Lippi, Mattiuzzi, Bovo, &
Plebani, 2020). In keeping with this and other observations, we can
suggest the NLRP3 inflammasome-mediated pyroptosis as one of the
key mechanisms involved in COVID-19 (Figure 1). Consequently, a
further exacerbation of symptoms may derive from the pyroptosis-
induced release of viral RNA and antigens that, by reaching the circu-
lation, may generate immune complex and depositions in other target
organs, initiating severe inflammatory cascades. Hence, in addition to
local damage, the cytokine storm also has ripple effects across the
body, evoking organ damage and multi-organ failure (Ruan, Yang,
Wang, Jiang, & Song, 2020).
F IGURE 1 The figure illustrates the
relationship between diabesity—the association of
obesity and diabetes—and SARS-CoV-2 infection
response. Diabesity increases the susceptibility to
exacerbation of COVID-19 throughout an
excessive metabolic inflammatory response that is
regulated, at least in part, by the NLRP3
inflammasome complex. The NLRP3
inflammasome is also a master regulator of the
cytokine storm and pyroptosis, both evoked by
SARS-CoV-2 infection
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4 | NLRP3 INFLAMMASOME AND
RESOLUTION OF INFLAMMATION
Resolution of inflammation is an active process triggered by the
onset of inflammation itself (Perretti & D'Acquisto, 2009). The main
actors of this process consist of specialized pro-resolving mediators
(SPMs), whose list is constantly updated and includes annexin A1
(AnxA1), formyl-peptide receptor 2 (FPR2), and lipoxin A4
(Brancaleone et al., 2013; Dufton et al., 2010; Norling, Dalli, Flower,
Serhan, & Perretti, 2012; Serhan, Chiang, & Dalli, 2015). Very
recently, AnxA1 has been reported to be involved in the regulation
of NLRP3 inflammasome function (Galvao et al., 2020), indepen-
dently from the binding to its cognate receptor FPR2 (Galvao
et al., 2020). Indeed, lower levels of AnxA1 are associated with an
increased activation of NLRP3, thus raising IL-1β release (Kelley,
Jeltema, Duan, & He, 2019). In addition, AnxA1 is also known to trig-
ger resolution pathway by engaging FPR2 (Brancaleone et al., 2011;
Machado et al., 2020; Perretti & D'Acquisto, 2009), and the AnxA1/
FPR2 signalling axis has been identified to control and limit viral
infection (Alessi, Cenac, Si-Tahar, & Riteau, 2017; Lopategi
et al., 2019). Therefore, impairment of this axis could unbalance the
immune response to infections, thus generating an ineffective
response, which in turn could lead to increased cytokine storm and
exacerbation of COVID-19 symptoms.
5 | DOES NLRP3 INFLAMMASOME
ACTIVATION DRIVE THE EXACERBATION OF
INFLAMMATION AND DISEASE PATHOLOGY
IN OBESE/DIABETIC PATIENTS WITH
COVID-19?
The specific reasons for the higher susceptibility of obese and diabetic
patients to SARS-CoV2 are unclear, but chronic exposure to a low-
grade NLRP3 inflammasome-dependent inflammatory response may
well be a key driver. Diet-induced alterations in the gut microbiome
and related increased gut leakiness of bacterial wall LPSs (endotoxins)
are known to promote activation of NLRP3 inflammasomes by toll-
like receptor (TLR) pathways. This event is followed by the accumula-
tion of IL-1 family cytokines, which modulate the function of the
insulin-producing pancreatic beta cells (Tack, Stienstra, Joosten, &
Netea, 2012). We and others have demonstrated that over-activation
of the NLRP3 inflammasome is involved not only in the pathogenesis
of diabesity but also in the exacerbation of related cardiovascular inju-
ries, including myocardial infarction, and this process is associated
with an increase in the local inflammatory response. At the same time,
a decrease in the efficiency of endogenous protective responses
occurs (Mastrocola, Collino, et al., 2016; Y. Xu et al., 2013). NLRP3
inflammasome activation is involved in endothelial lysosome mem-
brane permeabilization, cathepsin B release, and impaired glycocalyx
thickness (Ikonomidis et al., 2019), thus further contributing to the
enhanced susceptibility to cardiovascular injury. Similarly, the
diabesity-related basal activation of the NLRP3 inflammasome
cascade, leading to increase in either gastrointestinal or vascular per-
meability, may contribute to exacerbate SARS-CoV-2 systemic diffu-
sion and enhance the intricate mechanisms of intracellular crosstalk
operational in the pathogenesis of COVID-19.
6 | THE NLRP3 INFLAMMASOME AND
PHARMACOLOGICAL TREATMENTS FOR
COVID-19
To date, there are no specific medications available to treat COVID-
19. Clinical trials are in process on several drugs, mainly based on the
drug repurposing approach to redevelop a compound/drug for the
use in a different disease (COVID-19) other than that of its original
use. This review summarizes recent documentations on clinically
approved drugs, repurposed to counteract COVID-19 infection,
whose potential efficacy can be due, at least in part, to interference
with the NLRP3 inflammasome cascade, at different levels (Figure 2).
We systematically searched the PubMed and Google Scholar
databases, clinicaltrials.gov, chictr.org.cn/searchprojen.aspx, and
https://www.clinicaltrialsregister.eu until June 25, 2020, to prepare
this section of the narrative review on the role of the NLRP3
inflammasome in drugs repurposed in COVID-19. We also accessed
the full text of the relevant cross-references from the search results.
6.1 | Agents inhibiting activation of components of
the NLRP3 inflammasome complex
To date, no specific and selective compounds which inhibit the activa-
tion of the NLRP3 inflammasome are clinically available. Nonetheless,
several drugs have been proposed to exert their beneficial effects,
at least in part, by interfering with the activity of the NLRP3
inflammasome, although detailed mechanistic information on the
mode of inhibition is lacking for many of these molecules (Mangan
et al., 2018). One of the best characterized compounds used for
exploring NLRP3 biology and drug ability is MCC950, which binds to
NLRP3 and affects a key step in its activation (Coll et al., 2015). We
recently also characterized the pharmacological profile of a newly syn-
thesized NLRP3 inflammasome inhibitor, named INF4E, which directly
targets the NLRP3 inflammasome and inhibits the ATPase activity of
NLRP3 required for its activation (Mastrocola, Penna, et al., 2016).
6.1.1 | Interferons
Among the drugs under investigation for the treatment of COVID-19,
interferons (IFNs) are those whose effects observed may be, at least
in part, the result of altering activation of the NLRP3 inflammasome
pathway. Clinical trials are investigating the effects of IFNs either in
combination with lopinavir/ritonavir (Chinese Clinical Trial Registry
identifier: ChiCTR2000029387) or lopinavir/ritonavir/ribavirin
(NCT04276688 and EudraCT database identifier: 2020-001023-14).
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Selective interactions between type-I IFNs and NLRP3 inflamma-
somes have been documented. For instance, both type-I IFNs and IFN-
γ evoke higher expression of inducible NOS, increasing levels of
endogenous NO, which inhibits NLRP3 oligomerization by means of
direct S-nitrosylation of the NLRP3 protein, avoiding full inflammasome
organization (Mishra et al., 2013). Another mechanism resides in the
ability of type-I IFN to decrease the NLRP3 inflammasome activation
via the transcription factor STAT1, that induces caspase-1 to process
the IL-1β precursor (Kopitar-Jerala, 2017).
6.1.2 | Antiviral agents
The administration of the protease inhibitor ritonavir in association
with lopinavir has been tested for the treatment of SARS-CoV-2 infec-
tion and COVID-19 pneumonia (Cao et al., 2020), and there are sev-
eral ongoing clinical trials in China (NCT04255017, NCT04261907,
NCT04286503, and NCT04295551), Hong Kong (NCT04276688),
Republic of Korea (NCT04307693), and Europe (NCT04315948 and
NCT04328285). The protease inhibitor darunavir is under investiga-
tion as an alternative drug to lopinavir/ritonavir treatment in COVID-
19 (NCT04252274 and ChiCTR2000029541). Other two clinical trials
(NCT04261270 and NCT04303299) have been proposed to evaluate
oseltamivir, a neuraminidase inhibitor approved for the treatment of
influenza, alone or in combination with ritonavir or favipiravir,
darunavir, and chloroquine. Interestingly, the three antiviral drugs
here mentioned interfere with NLRP3 inflammasome activation.
Ritonavir has been demonstrated to inhibit caspase-1 activation
leading to reduced cleavage of pro-IL-18 (Weichold et al., 1999),
whereas darunavir limits the expression of key regulators of NLRP3
inflammasome complex formation, TLR4 and NF-κB (Zhang
et al., 2018). In contrast, oseltamivir had no effect on the expression
of NLRP3 and IL-1β, however, when administered in combination with
sirolimus, it drastically improves the ability of sirolimus to repress
NLRP3 inflammasome activation and NLRP3 inflammasome-mediated
secretion of IL-1β in lung epithelial cells infected with influenza virus
(Jia et al., 2018).
6.1.3 | Azithromycin
Few clinical trials are recruiting patients with COVID-19 to test the
efficacy of the known macrolide antibiotic azithromycin alone
(NCT04332107, NCT04381962, NCT04369365, and NCT04371107)
or in combination with hydroxychloroquine (NCT04339816 and
NCT04336332).
The beneficial effects of azithromycin against LPS-induced pul-
monary neutrophilia have been documented to involve NLRP3
inflammasome inhibition (Bosnar et al., 2011; Gualdoni et al., 2015),
which is also involved in mediating tetracycline beneficial effects in
experimental models of diabetic retinopathy and ischaemic stroke
(W. Chen, Zhao, et al., 2017; Lu, Xiao, & Luo, 2016).
F IGURE 2 An illustration of plausible NLRP3 inflammasome-related mechanisms targeted by clinically approved drugs, repurposed to manage
COVID-19. Following SARS-CoV-2 interaction with ACE2 receptors, NLRP3 inflammasome is up-regulated to induce immune response against
the virus. Overall, the over-activation of NLRP3 inflammasomes amplifies the innate immune response and contributes to cell death by pyroptosis
and virus propagation. HCQ, hydroxychloroquine
BERTOCCHI ET AL. 4925
6.1.4 | Immunosuppressants
Three clinical trials are recruiting COVID-19 patients to test the
efficacy of the immunosuppressant sirolimus (NCT04341675,
NCT04371640, and NCT04374903), whereas no clinical study on the
calcineurin inhibitor cyclosporine in COVID-19 has been recorded,
although it has been suggested as a potential treatment for SARS-
CoV-2 infection (Cure, Kucuk, & Cumhur Cure, 2020). Both these
immunosuppressants can interfere with NLRP3 inflammasome.
Sirolimus inhibits NLRP3 inflammasome activation in macrophages
through autophagy induction (Ko, Yoon, Lee, & Oh, 2017), whereas
cyclosporine targets cyclophilin D to prevent the opening of the mito-
chondria permeability transition pore, which is involved in NLRP3
inflammasome activation (Iyer et al., 2013).
Another well-known NLRP3 inhibitor included in several clinical
protocols for COVID-19 patients is the classical anti-mitotic drug
colchicine, with at least 10 ongoing clinical trials (NCT04328480,
NCT04322682, 2020-001841-38, NCT04392141, 2020-001511-25,
NCT04322565, NCT04375202, NCT04360980, 2020-001603-16,
and NCT04363437) and 3 others ready to start (NCT04367168,
NCT04355143, and NCT04326790). Several mechanisms have been
proposed to explain how colchicine can suppress NLRP3 inflammasome
activation. First, colchicine can inhibit the expression of pyrin gene,
preventing the assembly of the NLRP3 inflammasome complex (Nidorf,
Eikelboom, & Thompson, 2014). Second, colchicine inhibits activation
of caspase-1 and mature IL-1β (Otani et al., 2016). Third, colchicine
inhibits P2X7 receptor-induced pore formation, a key step in NLRP3
inflammasome activation following ATP exposure (Marques-da-Silva,
Chaves, Castro, Coutinho-Silva, & Guimaraes, 2011).
6.1.5 | Tranilast
Tranilast, an analogue of a tryptophan metabolite, which has been
used in allergic disorders such as bronchial asthma, has been recently
suggested for repurposing in the treatment of novel coronavirus
pneumonia (ChiCTR2000030002). As convincingly demonstrated
(Y. Huang et al., 2018), tranilast targets NLRP3 or NLRP3–ASC inter-
action to block the assembly of NLRP3 inflammasome, thus exerting
significant beneficial effects in experimental models of inflammation-
associated diseases.
6.2 | Agents inhibiting expression of components of
the NLRP3 inflammasome complex
Inhibition of NLRP3 inflammasome activation can be achieved by lim-
iting the expression of the main component of the inflammasome
complex, although this approach is not specific and is likely to produce
many off-target effects.
6.2.1 | JAK and Bruton's TK inhibitors
Low MW compounds with immunomodulatory properties, already
proposed for COVID-19 infection and with documented modulatory
activity on expression of NLRP3 inflammasome components, are the
JAK inhibitor baricitinib and the Bruton's TK (BTK) inhibitor
acalabrutinib. A study on baricitinib has already been concluded
with interesting results (NCT04358614), and others are recruiting
patients for both the treatments (baricitinib: NCT04320277 and
NCT04390464; acalabrutinib: NCT04346199 and NCT04380688).
Experimental evidence for key roles of the JAK and BTK cascades in
modulating expression of the NLRP3 inflammasome and diabesity
pathogenesis has been published (Collotta et al., 2020; Furuya
et al., 2018; Purvis et al., 2020).
Up to now, six clinical trials (NCT04347980, NCT04325061,
NCT04395105, NCT04344730, NCT04360876, and NCT04327401)
reported on clinicaltrials.gov are recruiting patients to test the efficacy
of the corticosteroid dexamethasone, whose beneficial effects in air-
way inflammation have been recently demonstrated to involve lung
inhibition of the activity of NLRP3 inflammasome and the release of
IL-1β and IL-18 (M. Guan, Ma, et al., 2020).
6.2.2 | Antimalarial agents
Chloroquine and its analogue hydroxychloroquine, two well-known
antimalarial drugs, have been proposed for severe COVID-19 treat-
ment, with more than 70 clinical trials registered on clinicaltrials.gov.
Several studies have demonstrated the anti-inflammatory activity of
chloroquine mainly due to significant inhibition of cytokine release,
including IL-1β, from monocytes and macrophages (Hong et al., 2004).
Recently, a direct role for chloroquine in inhibiting the expression of
NLRP3 inflammasome components has been demonstrated (X. Chen,
Wang, et al., 2017). Besides, hydroxychloroquine exerts its anti-
inflammatory effect by inhibiting cathepsin-mediated NLRP3
inflammasome activation (Tang et al., 2018). As recently reported
(Lucchesi et al., 2020), the pleiotropic effects of chloroquine and hydro-
xychloroquine on NLRP3 inflammasome expression and activation may
significantly contribute to the ability of these antimalarial drugs to
accelerate the recovery of patients with SARS-CoV-2-induced ARDS.
6.3 | Agents inhibiting NLRP3 inflammasome-
mediated effector mechanisms
Blocking downstream signalling molecules, such as IL-1β, may provide
a means to regulate NLRP3 inflammasome activation. However, the
efficacy of this approach is limited because NLRP3 induces a variety
of pro-inflammatory mediators in addition to IL-1β, and conversely,
the risk of immune suppression would be higher because IL-1β is pro-
duced by a variety of non-NLRP3 inflammasome-dependent pathways
in response to a variety of stimuli.
6.3.1 | Anti-IL-1 agents
There are at least eight clinical trials on pharmacological strategies
specifically aimed to target the main product of NLRP3 inflammasome
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activation, the cytokine IL-1β. They include studies on the human
anti-IL-1β monoclonal antibody canakinumab (clinicaltrials.gov
identifier: NCT04362813, NCT04365153, and NCT04348448)
and the recombinant non-glycosylated human IL-1 receptor
antagonist anakinra (NCT04324021, NCT04330638, NCT0432402,
NCT04357366, and NCT04339712). Besides, several other clinical tri-
als are evaluating the effects of drugs targeting IL-6, whose serum
concentrations are drastically increased in patients with NLRP3
inflammasome-mediated condition (Abbate et al., 2020). A crosstalk
mechanism linking IL-1β to IL-6 has been documented. IL-1β induces
IL-6 gene transcription via a PI3K / Akt-dependent pathways (Cahill &
Rogers, 2008), and, at the same time, blockade of IL-6 signalling blunts
the activation of NLRP3 inflammasome (Powell et al., 2015; Wu
et al., 2018). Thus, drugs able to interfere with IL-6 receptor activation
may inhibit NLRP3-dependent IL-1β release, and, in a similar way,
anti-IL-1β strategies significantly reduce IL-6 release, with an effective
control of the cytokine storm. Several clinical trials have been
approved to test the efficacy of sarilumab (NCT04315298
and NCT04327388, EudraCT identifier: 2020-001162-12 and
2020-001390-76) and tocilizumab (ChinaXiv identifier:
202003.00026 and 20000.30894), two humanized monoclonal anti-
bodies against the IL-6 receptor, thus confirming that targeting cellu-
lar machineries leading to cytokine overproduction, such as the
NLRP3 inflammasome, holds promise for COVID-19 therapy.
7 | CONCLUSIONS
Both infection and individual dysfunctional immune response elicited
by SARS-CoV-2 have been reported to contribute to COVID-19 path-
ogenesis. Thus, it is more than a speculation that controlling the
inflammatory response may be as important as targeting the virus.
The evidence here reported suggest a potential role for the NLRP3
inflammasome pathway as a crosstalk mechanism involved in both
cellular events. Indeed, pharmacological targeting of NLRP3
inflammasome could be a feasible approach to counteract the pathol-
ogy at multiple levels, ranging from the interference with viral infec-
tion to the reassessment of unbalanced immune responses. In
addition, patients with exacerbated disease might reveal an impaired
resolution process, which could again reflect on NLRP3 hyper-
activation contributing to the “cytokine storm.” Interestingly, some of
the pharmacological strategies under investigation for COVID-19
therapy include drugs able to directly disrupt the NLRP3
inflammasome cascade or to affect the transcriptional activity of fac-
tors involved in the synthesis of the main components of the NLRP3
inflammasome complex. Further studies are needed to better eluci-
date the pathophysiological involvement of NLRP3 inflammasome in
this specific context and to prove the efficacy and safety of related
pharmacological strategies. Overall, the findings here reviewed under-
lie intriguing perspectives within the intricate mechanisms involved in
the COVID-19 pathogenesis, and, thus, they may contribute to raise
hope for discovering new strategies to battle one of the major pan-
demics of our modern times.
7.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY
(http://www.guidetopharmacology.org) and are permanently archived in
the Concise Guide to PHARMACOLOGY 2019/20 (Alexander,
Christopoulos et al., 2019; Alexander, Fabbro et al., 2019a, b; Alexander,
Kelly et al., 2019; Alexander, Mathie et al., 2019).
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